TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00352976
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
Study: NCT00418613
Drug: Comparator: Placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0633 100mg Pbo capsules for a 12-wk treatment period
Study: NCT00967434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
Study: NCT00044057
Drug: YM872 (zonampanel), t-PA (alteplase)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01348217
Drug: chemotherapy: FOLFOX 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
Study: NCT02529852
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
Study: NCT02529852
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
Study: NCT03892564
Drug: MC2-01 Cream, no irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03892564
Drug: MC2-01 vehicle, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03892564
Drug: MC2-01 vehicle, no irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT03892564
Drug: Control, irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
Study: NCT01037985
Drug: EXC 001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT01037985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple intradermal injections of EXC 001 and placebo
Study: NCT01401023
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: : Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
Study: NCT03196973
Drug: DF289 plus DF277
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vial into the affected ear twice daily for 7 days
Study: NCT02039089
Drug: E2006 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039089
Drug: E2006 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02039089
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00408772
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00112840
Drug: CCI-779
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
Study: NCT01641341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule will not contain active treatment ingredients.
Study: NCT01018615
Drug: silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, 700 mg, twice daily, 12 days
Study: NCT00490802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00973115
Drug: Simvastatin CR
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01381809
Drug: Group 2: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
Study: NCT01381809
Drug: Group 1: Epoetin alfa
Approvals — FDA: no, EMA: no, PMDA: no
Description: type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
Study: NCT00803387
Drug: Travaprost without BAC (Travatan Z)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
Study: NCT00674479
Drug: INCB018424
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
Study: NCT00105313
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01440829
Drug: L-ornithine-L-aspartate
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
Study: NCT01261494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard gelatin capsules,oral administration,4 capsules per day before breakfast
Study: NCT00369408
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
Study: NCT02394028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
Study: NCT04433078
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 MG Tablet
Study: NCT04433078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet
Study: NCT01519752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied to affected area once a day for 28 days
Study: NCT00198289
Drug: Aurexis® (tefibazumab)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02981173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
Study: NCT04652349
Drug: HGP1910
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04652349
Drug: HCP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04652349
Drug: HGP1909
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT04652349
Drug: HGP1911
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take it once daily for 8 weeks orally.
Study: NCT00193726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a day for 5 days prior to each cycle of chemotherapy
Study: NCT01893879
Drug: placebo for study drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04261439
Drug: NIZ985
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIZ985 injection
Study: NCT02162550
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly injection
Study: NCT03381521
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The normal saline was used for injection solution
Study: NCT02903966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
Study: NCT03050814
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m\^2 intravenous (IV) over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
Study: NCT03050814
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625 mg/m\^2 twice a day by mouth. Part of the standard of care therapy.
Study: NCT02612844
Drug: NNC0143-0406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive one single dose only Subcutanesously (s.c., under the skin)
Study: NCT02425891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT02133820
Drug: 4 mg 12 hourly capsule - strong pain killer fed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02133820
Drug: 12 hourly capsule strong painkiller with antagonist fasted)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02133820
Drug: 4 mg 12 hourly capsule strong painkiller with antagonist fed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01991301
Drug: carfilzumib
Approvals — FDA: no, EMA: no, PMDA: no
Description: carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
Study: NCT02931214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02548806
Drug: Catapres 100μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catapres tablet 100μg, single dose
Study: NCT00281554
Drug: RSD1235
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT01488045
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
Study: NCT01040689
Drug: Placebo (for Tiotropium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Study: NCT01043601
Drug: Inhaled PT005
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled, twice daily for 1 week duration
Study: NCT01043601
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled, twice daily for 1 week duration
Study: NCT02355236
Drug: Naproxen/Esomeprazol 500/20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, b.i.d.
Study: NCT02355236
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, o.d.
Study: NCT02943577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT02355236
Drug: Naxozol-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (which is identical to Naxozol), b.i.d.
Study: NCT02355236
Drug: Comparator-Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule (which is identical to Celebrex), o.d.
Study: NCT03564288
Drug: SKI-G-801
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SKI-G-801 is administered as an IV infusion over 10 minutes
Study: NCT00127634
Drug: Human Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient specific dose, inhaled, before meals, 24 months, up to 36 months
Study: NCT04042220
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
Study: NCT02462811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02827487
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
Study: NCT02932579
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg
Study: NCT02827487
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
Study: NCT02827487
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
Study: NCT01370772
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: •FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
Study: NCT03410602
Drug: Subgingival irrigation
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
Study: NCT04401735
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT02932579
Drug: Oxycontin/acetominophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
Study: NCT00074711
Drug: Calcium Phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
Study: NCT00083551
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
Study: NCT00083551
Drug: Recombinant GM-CSF
Normalized name: recombinant human GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
Study: NCT02622802
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
Study: NCT02622802
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
Study: NCT00881686
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5mg/Kg adenosine will be administered intravenously before surgery
Study: NCT00006241
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00604955
Drug: Paromomycin sulfate
Normalized name: Paromomycin Sulfate
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
Study: NCT02379715
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01987843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03535558
Drug: Fluoroquinolone (FQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
Study: NCT03535558
Drug: Azithromycin (AZ)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
Study: NCT03530189
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
Study: NCT03530189
Drug: bolus of dextrose, reducing the glucose infusion, insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.
Study: NCT04918069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo ointment
Study: NCT04454151
Drug: Azithromycin Tablets
Normalized name: Azithromycin Tablets
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given PO Azithromycin 250 mg X1 daily, for 4 months, followed by a non-treatment follow-up period of 12 month.
Study: NCT00671190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally once daily for up to 5 days
Study: NCT02755116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo by mouth prior to anesthetic induction
Study: NCT00081263
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00783263
Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
Study: NCT00783263
Drug: Comparator: rosuvastatin 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
Study: NCT00783263
Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
Study: NCT00783263
Drug: Comparator: rosuvastatin 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
Study: NCT00421460
Drug: Testosterone Undecanoate,1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: duration for 4 injections
Study: NCT03606707
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-articular steroid injection for atlantoaxial joint
Study: NCT02219724
Drug: MOXR0916
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
Study: NCT00110864
Drug: PN2034
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01110486
Drug: ABT-348
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study: NCT01110486
Drug: ABT-348
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Study: NCT01110486
Drug: ABT-348
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
Study: NCT02265445
Drug: Deescalation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
Study: NCT00284258
Drug: CPT-11, 5-FU and l-LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
Study: NCT00998881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04134273
Drug: CLPG Topical Gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
Study: NCT04134273
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin Phosphate topical gel 1%
Study: NCT04134273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Study: NCT02949375
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel capsule to be taken daily for 28 days
Study: NCT02949375
Drug: Active Comparator:4.5mg GRI-0621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5mg GRI-0621 gel capsule to be taken daily for 28 days
Study: NCT02949375
Drug: Active Comparator: 6.0mg GRI-0621
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0mg GRI-0621 gel capsule to be taken daily for 28 days
Study: NCT00670813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period